As PBMs face threats in Wash­ing­ton, in­dus­try trade group poured mil­lions more in­to lob­by­ing

Per­haps no in­dus­try in health­care has seen its po­lit­i­cal for­tunes change faster than PBMs over the last two years.

It’s been just more than a year since De­moc­rats in DC fo­cused on the phar­ma-tar­get­ing In­fla­tion Re­duc­tion Act and its drug price re­forms. Phar­ma­cy ben­e­fit man­agers quick­ly be­came the next item on the tar­get list for law­mak­ers — from both par­ties — who want to bring down health­care costs and in­crease trans­paren­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.